Curative Biotechnology, Inc. Issues Letter to Shareholders
Curative Biotechnology (OTC: CUBT) issued a shareholder letter reviewing a year of progress on its metformin-based topical ophthalmology platform for degenerative retinal diseases, led by its program in intermediate- and late-stage Age-Related Macular Degeneration. On intellectual property, the Canadian IP Office (January) and the USPTO (July) issued Notices of Allowance covering topical metformin methods for retinal degeneration, including AMD and Stargardt's disease; Curative is the exclusive worldwide licensee of the underlying technology from the National Eye Institute.
Key figures
- Reverse split ratio
- 1-for-150
- Reverse split completed
- March 2026
- Shares outstanding pre split
- approximately 1.02 billion
- Shares outstanding post split
- approximately 6.8 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.